CapyFin

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2025 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

🇺🇸 NASDAQ:TXMD

Overview Earnings Dividends

Mar 02, 2021

•

Dec 31, 2020

TherapeuticsMD Q4 2020 Earnings Report

TherapeuticsMD reported a strong fourth quarter and full year with record total net product revenue.

Key Takeaways

TherapeuticsMD announced its Q4 and full-year 2020 financial results, highlighted by a 30% increase in total net product revenue for Q4 compared to Q3, and an 84% increase for the full year compared to 2019. The company also amended its financing agreement, updated net revenue covenants, and plans to pay down $50 million in debt.

Total net product revenue increased by 30% in Q4 2020 compared to Q3 2020.

ANNOVERA® net product revenue increased by 42% in Q4 2020 compared to Q3 2020.

The financing agreement was amended to update minimum net revenue covenants.

The company plans to pay down $50 million in debt.

Total Revenue

$22.6M

Previous year: $15.9M

+42.0%

EPS

-$7.5

Previous year: -$9.5

-21.1%

TherapeuticsMD

TherapeuticsMD

Company Overview

Full financial data and analysis

View TherapeuticsMD